Search - tctmd.com

Displaying 81 - 100 of 707

Sort: Relevancy | Date

Presentation TCT 2017

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Frederick Feit

November 01, 2017

Presentation TCT 2017

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Medical Therapy in Group I Pulmonary Arterial Hypertension: Efficacy and Safety

Presenter: Irene M. Lang, Ehtisham Mahmud, Rajesh Gupta

November 01, 2017

Presentation TCT 2017

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Samir R. Kapadia

November 01, 2017

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert-Jan van Geuns

November 01, 2017

Presentation TCT 2017

Should Pre-Diabetes Affect Revascularization Decisions?

Presenter: David J. Maron, Alan C. Yeung, Clemens von Birgelen

November 01, 2017

Presentation TCT 2017

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Presenter: David J. Maron, Alan C. Yeung, Michael E. Farkouh

November 01, 2017

Presentation TCT 2017

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung

November 01, 2017

Presentation TCT 2017

Is There a Preferred Stent for the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Upendra Kaul

November 01, 2017

Presentation TCT 2017

When Should PCI Be Preferred in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Sripal Bangalore

November 01, 2017

Presentation TCT 2017

When Should CABG Be Preferred in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Jack Boyd

November 01, 2017

Presentation TCT 2017

Worldwide Deaths and MI From Coronary Atherosclerosis: Scope of an Epidemic

Presenter: John A. Ambrose, Y. S. Chandrashekhar, James E. Muller

November 01, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Three

Shelley Wood

November 01, 2017

News Opinion Off Script TCT 2017

Off Script: Focusing on the Future

Kwan S. Lee

October 31, 2017

Presentation TCT 2017

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Presenter: Hiren Mistry, Michael A. Weber

October 31, 2017

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Presenter: Hiren Mistry, Michael A. Weber, Michael Böhm

October 31, 2017

Advertisement

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Medical Therapy in Group I Pulmonary Arterial Hypertension: Efficacy and Safety

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Should Pre-Diabetes Affect Revascularization Decisions?

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Is There a Preferred Stent for the Diabetic Patient?

When Should PCI Be Preferred in the Diabetic Patient?

When Should CABG Be Preferred in the Diabetic Patient?

Worldwide Deaths and MI From Coronary Atherosclerosis: Scope of an Epidemic

Live From Denver: TCT 2017, Day Three

Off Script: Focusing on the Future

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content